Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.97−0.53 (-0.55%)
Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –
Halozyme Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Halozyme Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $611.93M, down 11.7% year over year. For fiscal 2025 it was $480.40M, down 14.5% from the year before. The highest annual figure on record is $561.74M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.40M | -14.5% |
| FY2024 | Dec 31, 2024 | $561.74M | +61.1% |
| FY2023 | Dec 31, 2023 | $348.66M | +27.2% |
| FY2022 | Dec 31, 2022 | $274.02M | -1.7% |
| FY2021 | Dec 31, 2021 | $278.90M | +89.0% |
| FY2020 | Dec 31, 2020 | $147.54M | – |
| FY2019 | Dec 31, 2019 | -$63.54M | – |
| FY2018 | Dec 31, 2018 | -$66.94M | -180.5% |
| FY2017 | Dec 31, 2017 | $83.16M | – |
| FY2016 | Dec 31, 2016 | -$80.80M | – |
| FY2015 | Dec 31, 2015 | -$25.78M | – |
| FY2014 | Dec 31, 2014 | -$61.27M | – |
| FY2013 | Dec 31, 2013 | -$79.21M | – |
| FY2012 | Dec 31, 2012 | -$52.55M | – |
| FY2011 | Dec 31, 2011 | -$18.74M | – |
| FY2010 | Dec 31, 2010 | -$52.75M | – |
| FY2009 | Dec 31, 2009 | -$57.01M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $292.15M | +42.4% |
| Q1 FY2026 | Mar 31, 2026 | $188.74M | +30.9% |
| Q4 FY2025 | Dec 31, 2025 | -$89.59M | -150.3% |
| Q3 FY2025 | Sep 30, 2025 | $220.62M | +33.1% |
| Q2 FY2025 | Jun 30, 2025 | $205.14M | +71.2% |
| Q1 FY2025 | Mar 31, 2025 | $144.22M | +47.2% |
| Q4 FY2024 | Dec 31, 2024 | $178.15M | +71.4% |
| Q3 FY2024 | Sep 30, 2024 | $165.80M | +82.2% |
| Q2 FY2024 | Jun 30, 2024 | $119.84M | +23.2% |
| Q1 FY2024 | Mar 31, 2024 | $97.99M | +73.7% |
| Q4 FY2023 | Dec 31, 2023 | $103.97M | +34.9% |
| Q3 FY2023 | Sep 30, 2023 | $90.98M | +6.7% |
| Q2 FY2023 | Jun 30, 2023 | $97.26M | +176.6% |
| Q1 FY2023 | Mar 31, 2023 | $56.42M | -26.2% |
| Q4 FY2022 | Dec 31, 2022 | $77.07M | +34.5% |
| Q3 FY2022 | Sep 30, 2022 | $85.29M | +11.8% |
| Q2 FY2022 | Jun 30, 2022 | $35.16M | -62.5% |
| Q1 FY2022 | Mar 31, 2022 | $76.45M | +48.5% |
| Q4 FY2021 | Dec 31, 2021 | $57.31M | -26.9% |
| Q3 FY2021 | Sep 30, 2021 | $76.29M | +85.6% |
| Q2 FY2021 | Jun 30, 2021 | $93.85M | +209.2% |
| Q1 FY2021 | Mar 31, 2021 | $51.47M | – |
| Q4 FY2020 | Dec 31, 2020 | $78.42M | – |
| Q3 FY2020 | Sep 30, 2020 | $41.10M | – |
| Q2 FY2020 | Jun 30, 2020 | $30.36M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.37M | -159.8% |
| Q4 FY2019 | Dec 31, 2019 | -$31.02M | -6076.9% |
| Q3 FY2019 | Sep 30, 2019 | -$23.54M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.98M | – |
| Q1 FY2019 | Mar 31, 2019 | $3.96M | – |
| Q4 FY2018 | Dec 31, 2018 | $519.00K | -99.6% |
| Q3 FY2018 | Sep 30, 2018 | -$24.87M | -390.0% |
| Q2 FY2018 | Jun 30, 2018 | -$19.47M | – |
| Q1 FY2018 | Mar 31, 2018 | -$23.15M | – |
| Q4 FY2017 | Dec 31, 2017 | $126.42M | – |
| Q3 FY2017 | Sep 30, 2017 | $8.58M | – |
| Q2 FY2017 | Jun 30, 2017 | -$24.88M | – |
| Q1 FY2017 | Mar 31, 2017 | -$26.92M | – |
| Q4 FY2016 | Dec 31, 2016 | -$21.93M | – |
| Q3 FY2016 | Sep 30, 2016 | -$22.04M | – |
See a number that looks wrong?